Skip to main content
Clinical Trials/NCT07531420
NCT07531420
Completed
Not Applicable

Impact of Antibiotic Prophylaxis Modification on Surgical Site Infections Following Pancreaticoduodenectomy: The Role of Local Microbiological Ecology (ICADI Study)

Central Hospital, Nancy, France1 site in 1 country117 target enrollmentStarted: January 1, 2022Last updated:

Overview

Phase
Not Applicable
Status
Completed
Sponsor
Central Hospital, Nancy, France
Enrollment
117
Locations
1
Primary Endpoint
Surgical Site Infection rate within 30 days after pancreaticoduodenectomy

Overview

Brief Summary

Patients undergoing pancreaticoduodenectomy after preoperative biliary drainage are at increased risk of surgical site infections (SSI) due to bile colonization. Recent guidelines recommend the use of piperacillin/tazobactam instead of cephalosporins for antibiotic prophylaxis in this population. However, the relevance of this strategy may depend on local microbiological ecology.

This monocentric ambispective cohort study aims to compare SSI rates between two periods: before and after implementation of piperacillin/tazobactam prophylaxis. The study also evaluates microbiological profiles of bile cultures, antibiotic susceptibility, and postoperative antibiotic exposure.

The primary hypothesis is that adaptation of antibiotic prophylaxis to local ecology may optimize outcomes while limiting unnecessary exposure to broad-spectrum antibiotics.

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Other

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adult patients (\> 18 yrs)
  • Scheduled for pancreatic surgery
  • Presence of preoperative biliary stent
  • Postoperative admission to surgical ICU or intermediate care unit

Exclusion Criteria

  • decline to participate

Arms & Interventions

Period 1 (2022 - 2023)

Adult patients scheduled for pancreatic surgery receiving cefazolin as antibiotic prophylaxis

Period 2 (2024 - 202()

Adult patients scheduled for pancreatic surgery receiving piperacillin/taazobactam as antibiotic prophylaxis

Outcomes

Primary Outcomes

Surgical Site Infection rate within 30 days after pancreaticoduodenectomy

Time Frame: Day 30

Secondary Outcomes

  • Pancreatic fistula rate within 30 days after pancreaticoduodenectomy(Day 30)
  • Postoperative carbapenem exposure(Day 30)
  • Proportion of bacteria susceptible to cephalosporins and piperacillin/tazobactam(Day 1)

Investigators

Sponsor
Central Hospital, Nancy, France
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials